Gabapentin Capsule
Product Images NDC 68071-2876

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-2876). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2876 9)

Gabapentin 300 mg capsules label from NuCare Pharmaceuticals, Inc. The label states the package contains 90 capsules. Each capsule contains 300 mg of Gabapentin. Capsules are described as oblong, yellow opaque body with a caramel opaque cap, imprinted with "AHD" on the cap and "300" on the body. The label also includes manufacturing details, warnings, storage instructions, and multiple barcodes with NDC 68071-2876-9.*

FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

An equation illustrating the formula for calculating creatinine clearance (CLCr) based on patient age, weight, serum creatinine, and a correction factor for female patients. The formula includes variables for age in years, weight in kilograms, and serum creatinine in mg/dL.*

FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

Chemical structure of gabapentin, showing a cyclohexane ring attached to a central carbon bonded to an amino group (CH2NH2) and a carboxyl group (CH2CO2H).*

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

A line graph depicting mean pain scores over an 8-week period comparing placebo and Gabapentin at 3600 mg/day. The x-axis represents weeks, and the y-axis shows mean pain scores, with a 4-week dose titration period followed by a 4-week fixed dose period. Gabapentin shows a decrease in pain scores over time, while placebo remains relatively stable.*

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

A line graph depicting mean pain scores over a 7-week period comparing placebo and gabapentin at two dosages (1800 mg/day and 2400 mg/day). The x-axis represents time in weeks, divided into a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows the mean pain score, ranging from 0 to 10. Gabapentin groups show a greater decrease in pain scores compared to placebo.*

FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) treatments across two studies. Study 1 shows 12% for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

A scatter plot comparing differences (%) on the y-axis with daily doses (mg) of Gabapentin on the x-axis. The data points represent three separate studies labeled as Study a, Study b, and Study c with daily doses ranging from 600 mg to 1800 mg, showing variations in difference percentages across studies and doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.